Aurobindo Pharma Ltd. - Research Center
524804 AUROPHARMA Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 20 | Mar ' 20 | Sep ' 19 | Sep ' 18 | Sep ' 17 | |
|---|---|---|---|---|---|
| Sales | 7,944.04 | 6,965.99 | 6,300.49 | 5,729.21 | 5,262.15 |
| Operating profit | 2,171.97 | 1,499.77 | 1,185.98 | 1,003.73 | 1,527.83 |
| Interest | 16.85 | 38.77 | 56.81 | 54.67 | 22.27 |
| Gross profit | 2,329.32 | 1,659.59 | 1,188.59 | 956.06 | 1,546.06 |
| EPS (Rs) | 25.88 | 19.53 | 12.44 | 10.34 | 18.09 |
Half yearly
results in details
| Sep ' 20 | Mar ' 20 | Sep ' 19 | Sep ' 18 | Sep ' 17 | |
|---|---|---|---|---|---|
| Other income | 174.20 | 198.59 | 59.42 | 7.00 | 40.50 |
| Stock adjustment | -19.35 | -191.82 | -37.71 | -130.47 | -254.79 |
| Raw material | 3,624.63 | 3,545.99 | 3,201.56 | 3,042.96 | 2,460.29 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 851.31 | 809.85 | 751.62 | 651.09 | 531.07 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 1,315.48 | 1,302.20 | 1,199.04 | 1,161.90 | 997.75 |
| Provisions made | - | - | - | - | - |
| Depreciation | 239.93 | 237.40 | 233.08 | 194.60 | 173.00 |
| Taxation | 573.17 | 278.08 | 226.88 | 155.39 | 312.90 |
| Net profit / loss | 1,516.22 | 1,144.11 | 728.63 | 606.07 | 1,060.16 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 58.59 | 58.59 | 58.59 | 58.59 | 58.59 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 27.34 | 21.53 | 18.82 | 17.52 | 29.03 |
| GPM (%) | 28.69 | 23.16 | 18.69 | 16.67 | 29.16 |
| NPM (%) | 18.68 | 15.97 | 11.46 | 10.57 | 19.99 |
© 2020 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis